Condition: Metastatic Melanoma · BRAF Gene Mutation · Sponsor: Rina Plattner
This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerability and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of the combination of nilotinib with dabrafenib and trametinib or with encorafenib and binimetinib. Additionally, this study will assess pharmacokinetic parameters of dabrafenib and nilotinib when used in combination.
This description comes directly from the study's public registry record.
Heather Pavlik, RN · 859-323-7628 · heather.schroer@uky.edu
Always discuss trial participation with your own doctor first.
| University of Iowa | Iowa City, Iowa, United States | Not Yet Recruiting |
| Markey Cancer Center | Lexington, Kentucky, United States | Recruiting |
| St. Luke's University Health Network | Easton, Pennsylvania, United States | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04903119